Sirios Capital Management L P Acquires Shares of 30,524 Bristol-Myers Squibb Co (BMY)

Sirios Capital Management L P acquired a new position in Bristol-Myers Squibb Co (NYSE:BMY) in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund acquired 30,524 shares of the biopharmaceutical company’s stock, valued at approximately $1,895,000.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Wealth Architects LLC boosted its stake in shares of Bristol-Myers Squibb by 14.0% in the third quarter. Wealth Architects LLC now owns 6,923 shares of the biopharmaceutical company’s stock worth $430,000 after acquiring an additional 848 shares during the period. Beech Hill Advisors Inc. boosted its stake in shares of Bristol-Myers Squibb by 0.8% in the third quarter. Beech Hill Advisors Inc. now owns 105,500 shares of the biopharmaceutical company’s stock worth $6,549,000 after acquiring an additional 850 shares during the period. Signature Financial Management Inc. boosted its stake in shares of Bristol-Myers Squibb by 1.9% in the second quarter. Signature Financial Management Inc. now owns 46,006 shares of the biopharmaceutical company’s stock worth $2,546,000 after acquiring an additional 870 shares during the period. Mcmillion Capital Management Inc. boosted its stake in shares of Bristol-Myers Squibb by 1.4% in the second quarter. Mcmillion Capital Management Inc. now owns 64,044 shares of the biopharmaceutical company’s stock worth $3,544,000 after acquiring an additional 903 shares during the period. Finally, Securian Asset Management Inc boosted its stake in shares of Bristol-Myers Squibb by 0.5% in the second quarter. Securian Asset Management Inc now owns 167,108 shares of the biopharmaceutical company’s stock worth $9,248,000 after acquiring an additional 912 shares during the period. 72.74% of the stock is owned by institutional investors.

A number of research firms recently commented on BMY. Zacks Investment Research upgraded Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $70.00 target price on the stock in a research report on Friday, October 5th. Barclays boosted their target price on Bristol-Myers Squibb from $55.00 to $58.00 and gave the stock an “equal weight” rating in a research report on Friday, October 12th. Credit Suisse Group set a $61.00 target price on Bristol-Myers Squibb and gave the stock a “hold” rating in a research report on Sunday, October 14th. Morgan Stanley decreased their target price on Bristol-Myers Squibb from $63.00 to $59.00 and set a “hold” rating on the stock in a research report on Tuesday, November 6th. Finally, BMO Capital Markets decreased their target price on Bristol-Myers Squibb from $57.00 to $54.00 and set a “market perform” rating on the stock in a research report on Tuesday, October 23rd. Three equities research analysts have rated the stock with a sell rating, twelve have given a hold rating and seven have issued a buy rating to the company. The company has an average rating of “Hold” and an average target price of $61.73.

BMY stock traded up $0.45 during midday trading on Monday, reaching $53.91. 46,364 shares of the company traded hands, compared to its average volume of 8,126,931. Bristol-Myers Squibb Co has a 52-week low of $46.94 and a 52-week high of $70.05. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.53 and a quick ratio of 1.40. The company has a market cap of $87.26 billion, a PE ratio of 17.90, a price-to-earnings-growth ratio of 1.49 and a beta of 1.11.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, October 25th. The biopharmaceutical company reported $1.09 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.91 by $0.18. Bristol-Myers Squibb had a return on equity of 47.89% and a net margin of 6.50%. The business had revenue of $5.69 billion for the quarter, compared to the consensus estimate of $5.72 billion. Equities research analysts expect that Bristol-Myers Squibb Co will post 3.87 EPS for the current year.

TRADEMARK VIOLATION NOTICE: “Sirios Capital Management L P Acquires Shares of 30,524 Bristol-Myers Squibb Co (BMY)” was originally reported by Community Financial News and is the property of of Community Financial News. If you are reading this piece of content on another site, it was stolen and republished in violation of US & international trademark and copyright law. The original version of this piece of content can be viewed at https://www.com-unik.info/2018/12/03/sirios-capital-management-l-p-acquires-shares-of-30524-bristol-myers-squibb-co-bmy.html.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection.

Featured Article: Why is the conference call important?

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit